← Metformin × all-cause mortality

TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

Amir Sonnenblick et al.PubMed ↗Full text ↗Publisher ↗

  • Diabetes with no metformin treatmentlooks bad hereHigher disease-free survival, higher distant disease-free survival, higher overall survival.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Diabetes with no metformin treatment went with higher disease-free survival

+40%+1% to +94%

diabetes with no metformin treatment vs no history of diabetes at diagnosis

Bigger than 8 in 10 for all-cause mortality

As reported

HR 1.40, 95% CI 1.01–1.94

Correlation, not cause

Diabetes with no metformin treatment went with higher distant disease-free survival

1.6×1.1× to 2.2×

diabetes with no metformin treatment vs no history of diabetes at diagnosis

Bigger than 8 in 10 for all-cause mortality

As reported

HR 1.56, 95% CI 1.10–2.22

Correlation, not cause

Diabetes with no metformin treatment went with higher overall survival

1.9×1.2× to 2.9×

diabetes with no metformin treatment vs no history of diabetes at diagnosis

Bigger than 9 in 10 for all-cause mortality

As reported

HR 1.87, 95% CI 1.23–2.85

Who was studied, and how

8,381people with type 2 diabetes, in this paper

Already taking diabetes with no metformin treatment, or nottheir own situation, not assigned

on diabetes with no metformin treatment
not on history of diabetes at diagnosis

Diabetes with no metformin treatment went with higher disease-free survival+40%

Diabetes with no metformin treatment went with higher distant disease-free survival1.6×

Diabetes with no metformin treatment went with higher overall survival1.9×

correlation, not a test

the abstract, start to end

… DFS (multivariable hazard ratio [HR], 1.40; 95% CI, 1.01 to 1.94; P = .043), DDFS (multivariable HR, 1.56; 95% CI, 1.10 to 2.22; P = .013), and OS (multivariable HR, 1.87; 95% CI, 1.23 to 2.85; P = …

← favours treatmentfavours comparator →
could be chance
Disease-free survival (DFS)diabetes with no metformin treatment vs no history of diabetes at diagnosis
HR 1.401.01–1.94
Distant disease-free survival (DDFS)diabetes with no metformin treatment vs no history of diabetes at diagnosis
HR 1.561.10–2.22
Overall survival (OS)diabetes with no metformin treatment vs no history of diabetes at diagnosis
HR 1.871.23–2.85
MetforminAll-cause mortality
1 / 4

81 papers cite itlatest 60 shown

2017
…
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 28375706